Zobrazeno 1 - 10
of 12
pro vyhledávání: '"John Meekin"'
Autor:
Peter Zanvit, Dewald van Dyk, Christine Fazenbaker, Kelly McGlinchey, Weichuan Luo, Jessica M. Pezold, John Meekin, Chien-ying Chang, Rosa A. Carrasco, Shannon Breen, Crystal Sao-Fong Cheung, Ariel Endlich-Frazier, Benjamin Clark, Nina J. Chu, Alessio Vantellini, Philip L. Martin, Clare E. Hoover, Kenesha Riley, Steve M. Sweet, David Chain, Yeoun Jin Kim, Eric Tu, Nathalie Harder, Sandrina Phipps, Melissa Damschroder, Ryan N. Gilbreth, Mark Cobbold, Gordon Moody, Emily E. Bosco
Publikováno v:
The Journal of Clinical Investigation, Vol 133, Iss 22 (2023)
Prostate cancer is generally considered an immunologically “cold” tumor type that is insensitive to immunotherapy. Targeting surface antigens on tumors through cellular therapy can induce a potent antitumor immune response to “heat up” the tu
Externí odkaz:
https://doaj.org/article/e772d4b790a848fcb94aa4259efad645
Autor:
Yashaswi Shrestha, Ronald Herbst, Rajiv Raja, Maria Libera Ascierto, Michael Oberst, Philip Martin, Melissa de los Reyes, Nabendu Pore, Raymond Rothstein, John Meekin, Ashok K. Gupta, Melanie M. Frigault, Stephen Blackmore, Ina Bisha, Nathan Standifer, Shaad Essa Abdullah, Theresa Proia, Matthew Griffin, Phillip A. Dennis, Rebecca A. Halpin, Song Wu, Ricardo J Miragaia, Kathy Mulgrew, J. Carl Barrett, Maria Jure-Kunkel
Publikováno v:
Cancer Discovery. 11:2828-2845
Mutations in the STK11 (LKB1) gene regulate resistance to PD-1/PD-L1 blockade. This study evaluated this association in patients with nonsquamous non–small cell lung cancer (NSCLC) enrolled in three phase I/II trials. STK11 mutations were associate
Autor:
Dewald van Dyk, Peter Zanvit, Christine Fazenbaker, Kelly McGlinchey, Weichuan Luo, Jessica Pezold, John Meekin, Chien-ying Chang, Benjamin Clark, Philip L. Martin, Clare Hoover, Eric Tu, Ryan Gilbreth, Mark Cobbold, Gordon Moody, Emily E. Bosco
Publikováno v:
Cancer Research. 83:LB085-LB085
Prostate cancer is traditionally considered an immunologically “cold” tumor type rendering patients insensitive to immunotherapy. Targeting surface antigens on tumors through cellular therapy can induce a potent anti tumor immune response to “h
Autor:
Maria Letizia Giardino Torchia, Ryan Gilbreth, Ashley Merlino, Erin Sult, Noel Monks, Jon Chesebrough, Ravinder Tammali, Nina Chu, Jessica Tong, John Meekin, Kevin Schifferli, Kapil Vashisht, Karma DaCosta, Lori Clarke, Christina Gesse, Xiao-Tao Yao, Courtney Bridges, Gordon Moody
Publikováno v:
Cytotherapy. 24(7)
Chimeric antigen receptor (CAR) T cell therapy has yielded impressive clinical results in hematological malignancies and is a promising approach for solid tumor treatment. However, toxicity, including cytokine-release syndrome (CRS) and neurotoxicity
Autor:
Philip Howard, Cui Tracy Chen, Haihong Zhong, Nazzareno Dimasi, John Meekin, Paul Hynes, David A. Tice, Kenneth C. Anderson, Elaine M. Hurt, Xiaodong Xiao, Krista Kinneer, Reena Varkey, Yu-Tzu Tai, Ronald Herbst, Ryan Fleming, Shannon Breen, Suneetha Thomas, Binyam Bezabeh, Leslie Wetzel, Ruoyan Chen, Matt Flynn
Publikováno v:
Leukemia. 33:766-771
Autor:
John Meekin, Haihong Zhong, Maureen Kennedy, Rosa A. Carrasco, Ronald Herbst, Sandrina Phipps, Binyam Bezabeh, R. James Christie, Karma Dacosta, David A. Tice, Emily E. Bosco, Jiping Zha, Rakesh Dixit, Partha S. Chowdhury, Joanne Ayriss, Qun Du, Zhan Xiao, Darrin Sabol, MaryJane Hinrichs, Cui Chen, Shannon Breen, Lee Brown, Molly Reed
Publikováno v:
Oncotarget
Despite recent advances in treatment, breast cancer remains the second-most common cause of cancer death among American women. A greater understanding of the molecular characteristics of breast tumors could ultimately lead to improved tumor-targeted
Autor:
Krista Kinneer, Michael J. Wick, David A. Tice, John Meekin, Sriram Sridhar, Marlon Rebelatto, Alyssa Moriarty, Yu-Tzu Tai, Kenneth C. Anderson, Arnaud C. Tiberghien, Stephen J. Gregson, Christine Kiefer, Ronald Herbst, Sandrina Phipps, Luke Masterson, Philip Howard, Nazzareno Dimasi, Kyriakos P. Papadopoulos
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 24(24)
Purpose: Antibody–drug conjugates (ADC) utilizing noncleavable linker drugs have been approved for clinical use, and several are in development targeting solid and hematologic malignancies including multiple myeloma. Currently, there are no reliabl
Autor:
Binyam Bezabeh, Jonathan Rios-Doria, Jon Chesebrough, Philip Martin, David Stewart, John Meekin, Patrick Strout, Emil Michelotti, Raymond Rothstein, Cui Chen, Leslie Wetzel, Kelly McGlinchey, Robert E. Hollingsworth, Andrew Buchanan, Maureen Kennedy, Nazzareno Dimasi, Kathy Mulgrew, Ryan Fleming, Allison M. Marrero, Jay Harper
Publikováno v:
Cancer research. 77(10)
Immunogenic cell death (ICD) is the process by which certain cytotoxic drugs induce apoptosis of tumor cells in a manner that stimulates the immune system. In this study, we investigated whether antibody–drug conjugates (ADCS) conjugated with pyrro
Autor:
John Meekin, Sandrina Phipps, Yu-Tzu Tai, Krista Kinneer, Luke Masterson, Philip N. Howard, David A. Tice, Ryan Fleming, Sriram Sridhar, Ben T Ruddle, Arnaud C. Tiberghien, Kenneth C. Anderson, Ronald Herbst, Nazzareno Dimasi
Publikováno v:
Cancer Research. 78:567-567
Antibody drug conjugates (ADCs) combine a monoclonal antibody with a potent cytotoxic drug to preferentially eliminate antigen-positive cells for the treatment of cancer. ADCs bearing non-cleavable drug-linkers such as the pyrrolobenzodiazepine (PBD)
Autor:
Sandrina Phipps, Philip Howard, Binyam Bezabeh, Nazzareno Dimasi, Michael J. Wick, Christine Kiefer, Ronald Herbst, Alyssa Moriarty, Luke Masterson, Megan Groves, Ryan Fleming, David A. Tice, Arnaud C. Tiberghien, Marlon Rebelatto, John Meekin, Krista Kinneer
Publikováno v:
Molecular Cancer Therapeutics. 17:A138-A138
Antibody-drug conjugates (ADCs) combine a monoclonal antibody with a potent cytotoxic drug to preferentially eliminate antigen-positive cells for the treatment of cancer. ADCs bearing non-cleavable warheads such as the pyrrolobenzodiazepine (PBD) SG3